Show simple item record

dc.contributor.authorFoey, Andrew
dc.date.accessioned2018-10-24T10:43:00Z
dc.date.available2018-10-24T10:43:00Z
dc.date.issued2011-12-01
dc.identifier.issn1555-1431
dc.identifier.urihttp://hdl.handle.net/10026.1/12618
dc.description.abstract

Mucosal tolerance is central to efficient gastrointestinal tract function, tolerating food and commensal bacteria, whilst maintaining immune responsiveness to pathogens. Mucosal macrophages play a pivotal role in tolerance; whereas in inflammatory bowel disease, dysfunctional macrophages lead to tolerance breakdown, whereby commensals perpetuate inflammation. Macrophage subsets however, determine effector function: M1s are pro-inflammatory whereas M2s are antiinflammatory/regulatory. In addition to commensal bacteria, butyrate, a short chain fatty acid probiotic metabolite, may also modulate macrophage-mediated tolerance. The human monocytic cell line, THP-1, was used to investigate butyrate immunoregulation in M1 and M2 macrophages, generated by monocyte differentiation in the presence of PMA or vitamin D3 respectively. Butyrate modulation of LPS- and PGN-induced TNFα, IL-1β, IL-10 and NFkB was measured by sandwich ELISA and reporter gene assay, respectively. Data indicated butyrate suppresses LPS- and PGN-induced monocyte and M2 production of IL-1β and TNFα, M1-induced TNFa and IL-10 but failed to modulate Ml-induced IL-1β. Additionally, butyrate augmented M2 IL-10 production, LPS- and PGN-stimulatedMl and LPS-inducedM2 NFkB activity but failed to regulate PGN-induced M2 NF-kB. In conclusion, butyrate differentially regulates macrophage cytokine production and NFkB activation, which is subsetdependent and suggestive of a cautionary approach to butyrate use in treatment of mucosal inflammation. Copyright © 2011 by New Century Health Publishers, LLC.

dc.format.extent147-158
dc.language.isoen
dc.titleButyrate regulation of distinct macrophage subsets: Opposing effects on M1 and M2 macrophages
dc.typejournal-article
dc.typeJournal Article
plymouth.issue3-4
plymouth.volume6
plymouth.publication-statusPublished
plymouth.journalInternational Journal of Probiotics and Prebiotics
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.rights.embargoperiodNot known
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV